Sacred Journey Recovery Showcases Wolf Therapy at Empower Collaboration, Uniting with Thought Leaders in Behavioral Health
The Empower Collaboration, known for creating a platform where heart-led professionals come together to inspire collective change, attracted hundreds of clinicians, coaches, trauma experts, and advocates. Keynote voices such as David Meltzer, a globally recognized entrepreneur and humanitarian, set the tone for a weekend rooted in purpose, transformation, and unity. Meltzer, who has long championed mental health and service as a business cornerstone, shared the stage with leaders like Rachel Graham, founder of Healing Springs Ranch, and Dr. Josh Schwarzbaum, an ER physician focused on trauma-informed care. Each presentation served as a call to action to rethink behavioral health from a multidimensional lens, merging clinical excellence, community-based healing, and personal purpose.
Sacred Journey Recovery contributed to this dialogue by presenting its trailblazing Wolf Therapy initiative. This program has captured attention for its deep therapeutic impact on men healing from substance use disorders and co-occurring trauma. Unlike traditional talk therapy alone, Sacred Journey's Wolf Therapy sessions leverage the nonverbal, intuitive presence of socialized wolves to help clients confront fears, reconnect to their own power, and rewire patterns of detachment. The wolves, provided in collaboration with the Wolf Education Project, are not only symbols of strength and survival but also partners in the recovery process. When clients come face to face with these majestic animals, it invites them into an encounter that bypasses intellectual defenses and awakens emotional truth.
This program is part of Sacred Journey Recovery's broader model, which incorporates evidence-based addiction treatment practices such as Dialectical Behavioral Therapy (DBT), Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Narrative Therapy. Unlike conventional facilities, Sacred Journey interweaves these modalities into real-world experience through adventure therapy, wilderness outings, rites of passage weekends, and brotherhood-based peer support. Based in Vista, California, the center provides a safe space where men are called into deeper self-awareness, radical honesty, and transformative accountability.
As the nation confronts an epidemic of fentanyl, methamphetamine, alcohol, and prescription drug abuse—especially among men who have long felt disconnected from traditional therapeutic models—Sacred Journey is positioning itself as a leader in experiential, masculine-centered recovery. The Empower Collaboration was a fitting venue for this work to be highlighted. At a time when many are questioning the efficacy of outdated treatment systems, the event made it clear that innovation is not only welcome—it is essential.
CEO Drew Anagnostou shared his appreciation for the experience, stating, 'We are so grateful to be here at the Empower Collaboration event. Being able to share the stage with amazing thought leaders in the space is humbling and invigorating. Sacred Journey Recovery is poised to bring clinical excellence with holistic healing to men across the United States, based right here in Vista, California. We aim to help men reconnect with their authentic masculinity through outdoor-based adventure therapy, while also leveraging industry-leading technologies like Brain Mapping and cutting-edge therapies.'
With the national spotlight growing brighter on men's mental health and substance use, Sacred Journey Recovery's participation in the Empower Collaboration signals that the field is evolving. The presence of wolves in a therapeutic setting may seem unconventional to some, but for those in recovery at Sacred Journey, it is just one of many life-changing encounters on the path to wholeness. As conversations from the August event ripple across the behavioral health landscape, Sacred Journey Recovery remains at the forefront, committed to redefining what meaningful, masculine, and sustainable recovery truly looks like.
###
For more information about Sacred Journey Recovery, contact the company here:
Sacred Journey RecoveryDrew Anagnostou760-888-5202
[email protected]
161 Thunder Drive #214, Vista, California 92083
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
U.S. Pharmaceutical CDMO Market Valuation to Surpass USD 68.57 Billion by 2034
The U.S. pharmaceutical CDMO market is estimated at USD 39.14 billion in 2025 and is projected to reach approximately USD 68.57 billion by 2034, expanding at a CAGR of 6.43% over the forecast period. Ottawa, Aug. 13, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister firm of Precedence Research, the U.S. pharmaceutical CDMO market was valued at USD 36.77 billion in 2024 and is projected to reach approximately USD 68.57 billion by 2034, growing at a CAGR of 6.43%. The rising commercial scale-up in different therapeutic areas in the US and growing adoption of digital technologies are fueling overall market expansion. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways By product, the API segment dominated the U.S. pharmaceutical CDMO market in 2024 and is expected to grow fastest during the forecast period. By workflow, the commercial segment held the largest revenue share of the market in 2024. By application, the oncology segment registered dominance in the market in 2024. By end-use, the large pharmaceutical companies segment was dominant in the U.S. pharmaceutical CDMO market in 2024 and is expected to grow rapidly in the studies years. Market Overview & Potential Companies that are offering comprehensive services to different pharmaceutical and biotechnology companies, including both drug development and manufacturing in the US, are referred to as U.S. pharmaceutical CDMO market. Primarily, they provide expertise and resources for these companies. In 2025, they are focusing on novel drug discovery and development in oncology and other chronic conditions with the increased adoption of advanced production technologies. Moreover, the US is widely investing in robust and advanced infrastructure to fulfil the requirements of the increasing demand for specialized services, particularly in areas like biologics, sterile injectables, and gene and cell therapies. What are the Key Drivers Involved in The Growth of The Market? The U.S. pharmaceutical CDMO market has major dominating factors in its expansion, including crucial support to small and mid-sized pharmaceutical companies. These companies are facing the limitations of infrastructure for large-scale production with enhanced dependence on CDMOs for numerous stages of development and manufacturing. Also, benefits of pharmaceutical CDMOs, like scalability, flexibility, and cost-effectiveness, are fueling the expansion of the market with reduced capital investments. Besides this, experts working in CDMOs can navigate the complex regulatory landscape and check the compliance with standards like GMP (Good Manufacturing Practices). What are the Trends Associated with the U.S. Pharmaceutical CDMO Market? Different companies in the US are highly adopting outsourcing production to CDMOs to handle expenses and emphasis on competencies. Alongside, continuous advances in technologies and regulatory frameworks also play a crucial role in this market development. In May 2025, CDMO Piramal Pharma Solutions announced $90 million investment into its US manufacturing facilities. In March 2025, LGM Pharma, a global provider of customized API and CDMO services for the full drug product lifecycle, invested $6M in U.S. drug manufacturing capabilities for liquids, suspensions, semi-solids, and suppositories. You can place an order or ask any questions, please feel free to contact us at sales@ What Is the Emerging Challenge in the Market? Challenges connected with the U.S. pharmaceutical CDMO market include geopolitical stress, lack of raw material, and pandemic-related disturbances, are contribute as barriers in the production and delivery. Along with this, the rising need for a skilled workforce and specialized knowledge in continuous manufacturing and advanced bioprocessing demands vital investment in training and development. Country-level Analysis The U.S. pharmaceutical CDMO market is experiencing widespread expansion due to broader demand for a variety of biologics and biosimilars which are used in novel rare cases and other severe health issues. Besides this, ongoing technological breakthroughs in process chemistry and manufacturing automation are boosting the efficiency and quality of drug production, further propelling the adoption of CDMO services. As well as escalating cases of diverse cancers is assisting the development of novel cancer therapies, including targeted therapies and immunotherapies. For this market, In June 2025, Agenus Inc., a U.S.-based biotechnology company specializing in immuno-oncology, entered into a partnership with $141M Zydus investment to transform the immune-oncology area. Segmental Insights By product analysis How did the API Segment Lead the U.S. Pharmaceutical CDMO Market in 2024? The API segment was dominant in the market in 2024 and will grow rapidly during 2025-2034. An escalating demand for both traditional and complex APIs, especially in small molecule drugs, is fueling the segment's growth. In this segment, synthetic APIs experienced major demand, which are highly employed in numerous therapeutic areas such as cardiovascular, analgesic, and CNS drugs, making them an important driver in the API CDMO market. Also, this segment is moving towards continuous manufacturing, process analytical technology (PAT), sustainability, and digitalization, with enhanced focus on specialized CDMOs catering to niche therapeutic areas and expansion in biotech API development. Become a valued research partner with us - By workflow analysis What Made the Commercial Segment Dominant in the Market in 2024? In the U.S. pharmaceutical CDMO market, the commercial segment captured a major revenue share in 2024. Across the globe, one of the vital factors contributing to the overall market expansion is improved focus on the large-scale manufacturing of pharmaceuticals and biopharmaceuticals for commercial distribution. Moreover, widespread involvement of specialized expertise in biologics, cell & gene therapies, and mRNA vaccines necessitates sophisticated and specialized manufacturing capabilities. Additionally, CDMOs are boosting their service offerings by expanding collaboration with other organizations and companies to incorporate the complete drug development and manufacturing lifecycle, from early development to commercial launch. By application analysis How did Oncology Dominate the U.S. Pharmaceutical CDMO Market in 2024? The oncology segment registered dominance with the biggest share of the market in 2024. Eventual growth in cancer cases, with the progression of personalized therapies and targeted treatments, is impacting segment expansion. US CDMOs are stepping towards the transformation of advanced therapies, especially cell and gene therapies, antibody-drug conjugates, and bispecific antibodies, which are a major part of oncology clinical trials. These therapies are widely propelling demand for specialized facilities and expertise in handling potent APIs, cytotoxic compounds, and sterile injectables. By end-use analysis How did the Large Pharmaceutical Companies Hold a Major Share of The Market in 2024? The large pharmaceutical companies segment led the U.S. pharmaceutical CDMO market in 2024 and is anticipated to witness the fastest growth during 2025-2034. Nowadays, a rise in innovation investments, mainly in data analytics and AI, is assisting overall drug development processes and ultimately enhancing productivity. Apart from this, these companies are focusing on the utilization of advanced formulation technologies in specific areas, especially oral peptide formulations and permeation enhancers, to optimize drug delivery. These companies frequently grasp their robust infrastructure, scientific expertise, and global networks, which make them attractive for further collaborations and outsourcing to CDMOs in the US. Get the latest insights on healthcare industry segmentation with our Annual Membership: Ongoing Developments in the U.S. Pharmaceutical CDMO Market In July 2025, ESTEVE acquired Regis Technologies, a United States-based Contract Development and Manufacturing Organization (CDMO), to accelerate its contract development and manufacturing services for small-molecule active pharmaceutical ingredients from pre-clinical to commercial manufacturing in the US. In May 2025, Purdue University and a collaboration of leaders in AI, pharmaceutical manufacturing, and public policy launched a national effort in the Dirksen Senate Office Building to boost pharmaceutical manufacturing in the United States by revealing cutting-edge AI and advanced manufacturing technologies. In May 2025, Benuvia Operations, LLC, a U.S.-based global Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) supplier, signed a multi-year supply agreement with a prominent U.S. pharmaceutical company to support the company's product development activities. Key Players in the U.S. Pharmaceutical CDMO Market Adare Pharma Solutions AGC Biologics Agilent Technologies Catalent Pharma Solutions Exela Pharma Sciences PCI Pharma Services Pfizer CentreOne Scorpius BioManufacturing Sharp Services Single Use Support Thermo Fisher Scientific UPM Pharmaceuticals, Inc. Browse More Insights of Towards Healthcare: The global bioconjugation market reached USD 5.52 billion in 2024, rose to USD 6.37 billion in 2025, and will likely hit USD 23.18 billion by 2034, expanding at a CAGR of 15.46% from 2025 to 2034. The U.S. residual DNA testing market continues its upward trajectory and is set to generate substantial revenue growth, potentially reaching hundreds of millions by 2034. The worldwide life science CDMO market is expanding significantly and is projected to record several hundred million dollars in additional revenue by the end of the forecast period from 2025 to 2034. The global veterinary CRO and CDMO market stood at USD 7.17 billion in 2024, increased to USD 7.77 billion in 2025, and will likely reach USD 16.13 billion by 2034, growing at a CAGR of 8.43% between 2025 and 2034. The global investigational new drug CDMO market measured USD 5.29 billion in 2024, rose to USD 5.66 billion in 2025, and is forecast to reach USD 10.34 billion by 2034, expanding at a CAGR of 6.97% during the same period. The global advanced therapy medicinal products CDMO market stood at USD 6.73 billion in 2024, grew to USD 7.99 billion in 2025, and will likely surge to USD 37.27 billion by 2034, posting a CAGR of 18.82% between 2025 and 2034. The global mRNA therapeutics CDMO market valued at USD 4.62 billion in 2024, increased to USD 5.15 billion in 2025, and is projected to reach USD 13.63 billion by 2034, growing at a CAGR of 11.37% from 2025 to 2034. The CDMO services for pharma and biotech market is posting substantial growth from 2024 to 2034, fueled by rising outsourcing trends among pharmaceutical and biotech companies. The CDMO aseptic filling solutions market is recording robust growth and will continue booming through the forecast period, driven by growing demand for sterile manufacturing and specialized injectable therapies. The active pharmaceutical ingredients CDMO market stood at USD 127.45 billion in 2024, rose to USD 136.92 billion in 2025, and is projected to reach USD 260.98 billion by 2034, expanding at a CAGR of 7.43% from 2025 to 2034. Segments Covered in The Report By Product API Type Traditional API Highly Potent API Antibody-drug conjugate (ADC) Others Synthesis Synthetic Solid Liquid Biotech Drug Innovative Generics Manufacturing Continuous Manufacturing Batch Manufacturing Drug Product Oral Solid Dose Semi-Solid Dose Liquid Dose Others By Workflow Commercial Clinical By Application Oncology Small Molecules Biologics Infectious Diseases Neurological Disorders Cardiovascular Disease Metabolic Disorders Autoimmune Diseases Respiratory Diseases Ophthalmology Gastrointestinal Disorders Hormonal Disorders Hematological Disorders Others By End-Use Large Pharmaceutical Companies Medium Pharmaceutical Companies Small Pharmaceutical Companies Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Yahoo
6 hours ago
- Yahoo
ADCs Set for Growth Amid Regulatory Evolutions and Technological Advances
The Antibody Drug Conjugates Market presents opportunities in developing novel ADC platforms, expanding into new cancer types, and leveraging biomarker-driven patient selection. Growth is driven by increasing demand for targeted therapies, technological advancements, and investment in R&D despite competition and regulatory challenges. Antibody Drug Conjugates Market Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Small Molecule Drugs), Application, End User, Technology" report has been added to Antibody Drug Conjugates Market size is valued at USD 11.1 billion in 2025 and is projected to reach USD 42.2 billion by 2033, registering a compound annual growth rate (CAGR) of 18.2% over the forecast period. The Antibody Drug Conjugates (ADCs) Market focuses on the development and commercialization of targeted cancer therapies. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, delivering the drug directly to cancer cells while minimizing damage to healthy tissues. The market is driven by the increasing demand for targeted cancer therapies with improved efficacy and safety profiles. The market encompasses various ADC platforms, including linkers, payloads, and conjugation market is segmented based on target antigen, payload, linker, and application. The major target antigens include HER2, CD30, and CD33. The market caters to a diverse range of cancer types, including breast cancer, lymphoma, and leukemia. The market is characterized by intense competition among pharmaceutical and biotechnology companies, with a focus on developing novel ADC platforms and expanding the therapeutic applications of Antibody Drug Conjugates Market is subject to stringent regulatory requirements and evolving guidelines regarding cancer therapies. The market is also influenced by the increasing complexity of cancer biology and the need for highly specific and potent ADCs. The market is expected to continue its growth trajectory, driven by the increasing demand for targeted cancer therapies and the development of innovative ADC Insights: Antibody Drug Conjugates Market Development of novel ADC platforms with improved stability and efficacy. Expansion of ADC applications to solid tumors and other cancer types. Increasing use of biomarker-driven patient selection for ADC therapy. Growing interest in combination therapies involving ADCs and other cancer treatments. Rising adoption of next-generation sequencing and other technologies to optimize ADC development. Increasing prevalence of cancer and the need for effective treatments. Growing demand for targeted cancer therapies with improved safety profiles. Technological advancements in ADC development and conjugation technologies. Rising investment in research and development by pharmaceutical and biotechnology companies. Increasing availability of funding and partnerships for ADC development projects. High cost of ADC development and manufacturing. Complexity of ADC design and optimization. Challenges in delivering the payload to cancer cells and minimizing off-target effects. Evolving regulatory requirements and intellectual property considerations. Competition from alternative cancer therapies, such as immunotherapy and cell therapy What's Included in the Report? Global Antibody Drug Conjugates market size and growth projections, 2024-2034 North America Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (United States, Canada, Mexico) Europe market size and growth forecasts, 2024-2034 (Germany, France, United Kingdom, Italy, Spain) Asia-Pacific Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (China, India, Japan, South Korea, Australia) Middle East Africa Antibody Drug Conjugates market size and growth estimate, 2024-2034 (Middle East, Africa) South and Central America Antibody Drug Conjugates market size and growth outlook, 2024-2034 (Brazil, Argentina, Chile) Antibody Drug Conjugates market size, share and CAGR of key products, applications, and other verticals, 2024-2034 Short- and long-term Antibody Drug Conjugates market trends, drivers, challenges, and opportunities Antibody Drug Conjugates market insights, Porter's Five Forces analysis Profiles of 5 leading companies in the industry - overview, key strategies, financials, product portfolio and SWOT analysis Latest market news and developments Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2033 Estimated Market Value (USD) in 2025 $11.1 Billion Forecasted Market Value (USD) by 2033 $42.2 Billion Compound Annual Growth Rate 18.2% Regions Covered Global Antibody Drug Conjugates Market Segmentation By Product Type: Monoclonal Antibodies Small Molecule Drugs By Application: Oncology Autoimmune Diseases Infectious Diseases By End User: Hospitals Specialty Clinics Research Institutes By Technology: Chemical Linkers Bioconjugation Techniques By Distribution Channel: Direct Sales Distributors By Geography: North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Drug Conjugates Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Business Upturn
7 hours ago
- Business Upturn
Your Pump Is Trying to Tell You: You Need a Better Nursing Bra
New York, NY, Aug. 15, 2025 (GLOBE NEWSWIRE) — Most moms begin their breastfeeding journey with a pump and a bra, often purchased separately. Both may seem like smart choices, but when used together, they often don't align. Hands-free turns into hands-on. Leaks happen. Comfort disappears. Instead of gaining time and freedom, moms are stuck adjusting gear and rethinking their setup. Even the best breastfeeding bras can fall short if they are not designed to support a pump. For Breastfeeding Month 2025, Momcozy introduces a better solution. These three new kits combine wearable pumps with bras built to support them from the start. Awaken the Imagination of Comfort Many moms expect wearable pumps to offer convenience, flexibility, and more time for themselves. Pairing them with a hands-free pumping bra sounds like the perfect plan. But in reality, the comfort often doesn't last. The pump slips. The bra sags or digs in. Leaks start. Pressure builds. What once felt promising becomes another frustrating task in an already full day. The issue often isn't the pump or the bra alone. It's that they were never designed to function as a system. This disconnect can turn pumping from a moment of ease into a daily stressor. Real-Life Struggles: When Breast Pumps and Nursing Bras Don't Work Together, Moms Endure the Discomfort Even with careful product choices, mismatches happen. 'I carefully chose both my breast pump and nursing bra. Why do they still feel either too tight or too stuffy when used together? The whole pumping experience feels unstable and uncomfortable.' 'I want to turn the pump on with one hand, but the bra clasp keeps getting in the way. The nursing opening is made only for direct breastfeeding. There's no room for the pump. I fumble awkwardly, and it ruins my whole pumping rhythm.' When pumps and bras fail to work together, the fix isn't always a new product. It's a new approach. How Momcozy Solves It: Every Pump Deserves Its Perfect Match Momcozy designs pumps and bras as one unified solution. This dual-category approach ensures they function together to deliver support, comfort, and ease in real-life use. Each kit combines a specific pump with a supportive breastfeeding bra that secures the pump properly and fits comfortably. These sets were developed using real feedback from moms, especially those who experienced leaks, pinching, and shifting gear. The goal is not just product compatibility but relief from repeated discomfort. Meet the Three Kits Moms don't need more tools. They need the right ones to work together. Each Momcozy kit is created to solve a specific daily challenge. Momcozy Pro Breastfeeding Kit: Mobile Flow Hands-free Breast Pump ✖ Jelly Strip Support Nursing Bra Working moms often have tight schedules and few private spaces to pump. This kit supports those fast, pressured moments. The Mobile Flow Pump delivers efficient expression during short breaks without sacrificing output. The hands-free pumping bra is built with jelly strip support that wraps gently around the chest, holding the pump in place without wires. Whether sitting through a meeting or pumping in a shared space, moms can stay focused without distractions, leaks, or gear adjustments. Momcozy Breastfeeding Starter Kit: M5 All-in-One Breast Pump ✖ Ultra Soft Nursing Bra The early days of breastfeeding can feel overwhelming. This kit is designed to make that transition easier. The M5 Pump uses a baby-suckling rhythm that mimics natural feeding and reduces nipple pain. Paired with a buttery-soft nursing and pumping bra that stretches and adapts to postpartum body changes, this set surrounds first-time moms in all-day comfort and flexibility, helping them build confidence from the very first pump. The bra stays soft and supportive throughout the day, even as the body shifts. Momcozy Naturally Safe Breastfeeding Kit: Wearable Breast Pump V1Pro ✖ U.S. Cotton Nursing Bra For moms with sensitive skin or higher output needs, this kit offers durable comfort. The V1Pro delivers hospital-grade suction while keeping the motor away from the chest, which helps reduce heat and irritation during long sessions. The US Cotton Bra is made from American-grown cotton. It's breathable, hypoallergenic, and moisture-wicking for long-lasting freshness. Together, this set continues to deliver effective, safe, and gentle care for delicate skin. Why Choose Momcozy Momcozy leads with a simple belief: moms need gear that works with them, not against them. The Comfort+ experience combines thoughtful design with real-life insight to eliminate friction points that disrupt pumping. Comfort +, Momcozy's innovation framework, drives every product. From suction efficiency to fabric choice, each part supports the next. The brand's dual-category approach means breast pumps and nursing bras are never designed in isolation. They are built to solve everyday pain points together. This focus on integration helps moms pump more comfortably, adjust less often, and feel more confident throughout their breastfeeding journey. About Momcozy Momcozy is a trusted brand in wearable breast pumps and nursing bras, serving millions of mothers around the world. They focus on comfort, practicality, and real-life needs. From pregnancy through postpartum, Momcozy supports every stage of the breastfeeding journey with products that make daily life a little easier. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
